¼¼°è È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå : Á¦Ç°º°, ¹æ¹ýº°, ÃÖÁ¾ »ç¿ëÀÚº°, ±¹°¡º°, Áö¿ªº° »ê¾÷ ºÐ¼® - ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À² ¿¹Ãø(2023³â-2030³â)
Respiratory Syncytial Virus Diagnostics Market, By Product, By Method, By End-User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
»óǰÄÚµå : 1419100
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 01¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 288 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,474,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,401,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,778,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ ÇÏÀ̶óÀÌÆ®

È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå ±Ô¸ð´Â 2022³â 9¾ï 3,189¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2023³âºÎÅÍ 2030³â±îÁö º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.63%·Î È®´ëµÉ Àü¸ÁÀÔ´Ï´Ù.

È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå - ½ÃÀå ¿ªÇÐ

È£Èí±â °¨¿°ÀÇ À¯º´·ü Áõ°¡¿Í ü¿Ü Áø´ÜÁ¦¿¡ ´ëÇÑ ³ôÀº ¼ö¿ä°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁø

½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº È£Èí±â °¨¿°·ü Áõ°¡, ½Å»ý¾Æ ¼ö Áõ°¡, Æ÷ÀÎÆ® ¿Àºê ÄÉ¾î ½Ã¼³ ¹× ü¿Ü Áø´ÜÁ¦¿¡ ´ëÇÑ ³ôÀº ¼ö¿äÀÔ´Ï´Ù. È£Èí±â °¨¿°ÀÇ ¼ö´Â ¸¸¼º ÁúȯÀÇ ¼¼°è ¹ß»ý·ü°ú ÇÔ²² Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ °¨¿°Àº ½Å¼ÓÇÑ Áø´Ü°ú Ä¡·á·Î ¿¹¹æÇÒ ¼ö ÀÖ´Â ½Å»ý¾Æ »ç¸ÁÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ¾ú½À´Ï´Ù. ¼¼°è ½ÃÀåÀº ƯÈ÷ 2¼¼ ¹Ì¸¸ ¼Ò¾Æ¿¡¼­ È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º °¨¿°(RSV)ÀÇ ÀÌȯÀ²ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó °ßÀεǰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ °Ç°­ °ü¸® ÀÎÇÁ¶ó ÅõÀÚ Áõ°¡¿Í ÀÚ³àÀÇ °Ç°­¿¡ ´ëÇÑ ºÎ¸ðÀÇ °ü½É Áõ°¡¿Í °°Àº ¿äÀεµ ÀÖÀ¸¸ç ½ÃÀåÀº ¼øÁ¶·Ó°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. Áø´Ü±â¼úÀÇ °¡¿ë¼º°ú Á¶±âÁø´Ü¿¡ ÀÇÇÑ »ýÁ¸À²ÀÇ ³ôÀÌ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡µµ ½ÃÀå°³¹ß¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. »óȯ °¡À̵å¶óÀÎ, °è¹ß Ä·ÆäÀÎ, ¹«·á Áø´Ü µî Á¤ºÎÀÇ Àû±ØÀûÀÎ ÇÁ·Î±×·¥µµ ½ÃÀå È®´ë¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ¼¼°è ½ÃÀåÀº Á¦Ç°, ¹æ¹ý, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Ç°Àº ŰƮ ½Ã¾à, Àåºñ µîÀ¸·Î ºÐ·ùµË´Ï´Ù : ½ÃÀåÀ» µ¶Á¡ÇÏ´Â °ÍÀº ŰƮ ½Ã¾à ºÎ¹®ÀÔ´Ï´Ù. RSV Ç׿ø°Ë»ç¿ë ŰƮ½Ã¾à ¼ö¿ä Áõ°¡°¡ ½ÃÀå ¼ºÀåÀ» ²ø¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀº ¹æ¹ý¿¡ µû¶ó 7°¡Áö ¹üÁÖ·Î ºÐ·ùµÈ´Ù: Ç׿ø ½Å¼Ó Áø´Ü¹ý(RADT), ºÐÀÚÁø´Ü¹ý, Å©·Î¸¶Åä±×·¡ÇÁ ¸é¿ª ÃøÁ¤¹ý, ¿µ»ó Áø´Ü¹ý, Á© ¸¶ÀÌÅ©·Î µå·Ó·¿, À¯µ¿ ¼¼Æ÷ÃøÁ¤¹ý µî. Å©·Î¸¶Åä±×·¡ÇÁ ¸é¿ªÃøÁ¤¹ýÀÌ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È¿¡µµ ±× ¿ìÀ§¼ºÀ» À¯ÁöÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. Ç׿ø ½Å¼Ó Áø´Ü °Ë»ç(RADT)´Â COVID-19ÀÇ ¿ì·Á·Î ÃÖ±Ù ¼ö¿ä°¡ ³ô½À´Ï´Ù.

½ÃÀåÀº ÃÖÁ¾ »ç¿ëÀÚº°·Î º´¿ø, ÀçÅÃÄ¡·á ¹× Ŭ¸®´Ð µî 3°¡Áö·Î ºÐ·ùµÈ´Ù . ÀçÅà ÄÉ¾î ¹× Å¬¸®´Ð ºÎ¹®Àº ½ÇÇè½Ç Á¶»ç ¹× °Ë»ç ¿ä±¸°¡ ³ô±â ¶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå - Áö¸®Àû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î, ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °¢ Áö¿ªÀ¸·Î ÆÛÁ® ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ Àü°³ÇÏ´Â ±¹°¡¿¡ µû¶ó ´õ ³ª´¹´Ï´Ù.

È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå - °æÀï ±¸µµ :

RSV Áø´Ü ¾à¹° ½ÃÀåÀº ¸Å¿ì °æÀïÀÌ ½ÉÇÕ´Ï´Ù. Á¦Ç° Æ÷Æ®Æú¸®¿À¸¦ °³¼±Çϰí Á¦°øÇÏ´Â Á¦Ç°ÀÇ ¸Å·ÂÀ» ³ôÀ̱â À§ÇØ ÁÖ¿ä ±â¾÷Àº M&A ¹× ½ÅÁ¦Ç° ¼Ò°³¿Í °°Àº Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â ´õ ³ªÀº °Ë»ç¸¦ À§ÇØ »õ·Î¿î È£Èí±â ÆÐ³ÎÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº Novartis AG, Abbott, La Roche µîÀ» Æ÷ÇÔÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´ÜÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´ÜÀÇ ¾÷°èÀÇ Á¶»ç

Á¦5Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå »óȲ

Á¦7Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå - Á¦Ç°º°

Á¦8Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå-¹æ¹ýº°

Á¦9Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå - ÃÖÁ¾ »ç¿ëÀÚº°

Á¦10Àå È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ½ÃÀå-Áö¿ªº°

Á¦11Àå ÁÖ¿ä º¥´õ ºÐ¼® - È£Èí±â ¼¼Æ÷ À¶ÇÕ ¹ÙÀÌ·¯½º Áø´Ü ¾÷°è

Á¦12Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Respiratory Syncytial Virus Diagnostics Market size was valued at USD 931.89 Million in 2022, expanding at a CAGR of 9.63% from 2023 to 2030.

For Respiratory Syncytial Virus (RSV), rapid RSV antigen tests are the most often used test. They look for specific proteins from the RSV virus known as antigens in a fluid sample taken from your nose. RSV antigens cause the virus to be attacked by your immune system.

Respiratory Syncytial Virus Diagnostics Market- Market Dynamics

Increasing prevalence of respiratory infections and high demand for in-vitro diagnostics to propel market demand

The main drivers propelling the market expansion are the rising rate of respiratory infections, the growing number of newborns, and the high demand for point-of-care facilities and in-vitro diagnostics. It is predicted that the number of respiratory infections will rise along with the global incidence of chronic illnesses. These infections are a major cause of death in newborns, although they can be prevented with prompt diagnosis and treatment. The worldwide market is being driven by the increasing incidence of respiratory syncytial virus diagnostic (RSV) sickness, especially in children under the age of two years.

Furthermore, due to the factors like rising healthcare infrastructure investments and parents' growing concern for their children's health, the market is growing favorably. The availability of diagnostic technologies and growing awareness of the great survival rates that follow early diagnosis are also having a favorable effect on the market's development. Positive government programs, such as reimbursement guidelines, awareness campaigns, and free diagnostics, among others, contribute to the market's expansion.

Respiratory Syncytial Virus Diagnostics Market- Key Insights

Respiratory Syncytial Virus Diagnostics Market- Segmentation Analysis:

The Global Respiratory Syncytial Virus Diagnostics Market is segmented on the basis of Product, Method, End-User, and Region.

The market is divided into three categories based on Product: kits & reagents, instruments, and others. The kits & reagents segment dominates the market. Increasing demand for kits & reagents for RSV antigen tests is expected to boost the market growth.

The market is divided into seven categories based on Method: rapid antigen diagnostic test (RADTs), molecular diagnostics, chromatographic immunoassay, diagnostic imaging, gel microdroplets, flow cytometry, and others. The chromatographic immunoassay segment dominates the market and is likely to maintain its dominance during the forecast period. The rapid antigen diagnostic test (RADTs) has witnessed high demand in recent years due to COVID-19 concerns.

The market is divided into three categories based on End-User: hospitals, homecare & clinics, and others. The hospitals segment dominates the market and is likely to maintain its dominance during the forecast period. The homecare & clinics segment is expected to grow at a significant CAGR over the forecast period due to high need for laboratory research and testing.

Respiratory Syncytial Virus Diagnostics Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Respiratory Syncytial Virus Diagnostics Market- Competitive Landscape:

RSV diagnostics market is highly competitive as the industry is seen as being extremely competitive. To improve their product portfolios and increase the attractiveness of their offerings, the major players employ strategies like mergers and acquisitions and the introduction of new products. The companies engage in developing new respiratory panels for better testing. Key player in the market includes Novartis AG, Abbott, La Roche, etc.

Recent Developments:

In November 2021, QIAGEN introduced and obtained CE-marking for the QIAstat-Dx Respiratory 4 Plex Flu A-B/RSV/SARS-CoV-2 test.

In September 2021, La Roche introduced a collection of three PCR diagnostic test panels based on molecular polymerase chain reaction technology. These panels are precisely designed to concurrently detect and distinguish various common respiratory pathogens.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET KEY PLAYERS

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET, BY PRODUCT

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET, BY METHOD

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET, BY END-USER

GLOBAL RESPIRATORY SYNCYTIAL VIRUS DIAGNOSTICS MARKET, BY REGION

Table of Contents

1. Respiratory Syncytial Virus Diagnostics Market Overview

2. Executive Summary

3. Respiratory Syncytial Virus Diagnostics Key Market Trends

4. Respiratory Syncytial Virus Diagnostics Industry Study

5. Respiratory Syncytial Virus Diagnostics Market: COVID-19 Impact Analysis

6. Respiratory Syncytial Virus Diagnostics Market Landscape

7. Respiratory Syncytial Virus Diagnostics Market - By Product

8. Respiratory Syncytial Virus Diagnostics Market - By Method

9. Respiratory Syncytial Virus Diagnostics Market - By End-User

10. Respiratory Syncytial Virus Diagnostics Market- By Geography

11. Key Vendor Analysis- Respiratory Syncytial Virus Diagnostics Industry

12. 360 Degree Analyst View

13. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â